Keryx Biopharmaceuticals Inc (KERX.OQ)
|Market Cap (Mil.):||$1,362.33|
|Shares Outstanding (Mil.):||89.22|
- Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the drug could achieve blockbuster status.
(Adds details from conference call, analyst comments, background; updates share movement)
Nov 5 - Keryx Biopharmaceuticals Inc said its kidney drug met the main goals of a mid-stage study in patients with chronic kidney disease who were not on dialysis.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,928||-16.00|
|Astellas Pharma Inc (4503.T)||¥6,438||-67.00|
|Pfizer Inc. (PFE.N)||$32.35||-0.08|
|Novartis AG (NOVN.VX)||CHF72.60||-0.25|
|Merck & Co., Inc. (MRK.N)||$57.20||-0.27|
|Bayer AG (BAYGn.DE)||€96.44||-0.27|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€75.09||+0.19|
|Eli Lilly and Co (LLY.N)||$58.60||+0.00|
|Amgen, Inc. (AMGN.OQ)||$125.14||+2.88|
Earnings vs. Estimates
Analyst Research Reports
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Keryx Biopharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.